乙型肝炎病毒（Hepatitis B virus,HBV）感染是重要的公共卫生问题，估计全球流行率为3.8%，影响全球约2.96亿人。慢性乙型肝炎（chronic hepatitis ...

编者按在慢性乙型肝炎（CHB）的治疗领域，追求功能性治愈已逐步成为共识，但这并不意味着放弃对疾病的根治追求。2024年12月20~22日，在首届“井冈星火”消化肝病高峰论坛上，北京大学医学部庄辉院士在会上作了关于“功能性治愈是CHB治疗的主要终点”的 ...

HBV）肝硬化患者发生肝细胞癌（Hepatocellular carcinoma，HCC）的直接影响尚不清楚。近期，发表于Clinical Gastroenterology and Hepatology（IF：11.6）的研究对此 ...

The following is a summary of “Cobalt chloride-mimicked hepatocyte cell hypoxia induces TREX1 leading to Hepatitis B virus ...

This study identifies sociodemographic and health factors predictive of developing HCC among a cohort of people with chronic HBV or HCV infection ... Institute for Cancer Research Health Services ...

Background and Aim: The incidence of hepatocellular carcinoma (HCC ... occurs among a population chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV).

Hepatitis B virus (HBV) infection contributes to hepatocellular carcinoma (HCC) tumorigenesis, drug resistance, and recurrence, although the underlying molecular mechanisms remain unclear.

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Hepatocellular Carcinoma.

HBV remains a major global health burden, affecting over 250 million people worldwide. It is a leading cause of liver cancer, responsible for 50%–80% of hepatocellular carcinoma cases globally.

SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T Cell (TCR-T) therapy, SCG101. The therapy ...